StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Ubrelvy (ubrogepant) — U.S. reported growth YoY by Quarter

Ubrelvy (ubrogepant) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Ubrelvy (ubrogepant) — U.S. reported growth YoY: 15.0% in Q2 2026, down 31.5 pts from a year earlier.

Latest, Q2 2026
15.0%
Period ended Jun 30, 2026
Change on a year earlier
-31.5 pts
46.5% in Q2 2025
History
18 quarters
Since Q1 2022
Sources
18
Documents cited below

Where the Q2 2026 figure comes from

“|| Ubrelvy | 379 | 13 | 392 | 15.0 | 54.9 | 16.0 | 52.5 | 15.9”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUbrelvy (ubrogepant) — U.S. reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202615.0%-31.5 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202641.7%+24.1 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202512.3%-16.6 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202531.4%+17.8 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 202546.5%+29.9 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202517.6%-13.9 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202428.9%+12.0 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202413.6%-30.1 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202416.6%+12.1 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202431.5%+22.5 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202316.9%+9.4 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202343.7%+45.1 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20234.5%-43.1 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20239.0%-61.0 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20227.5%–Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 2022-1.4%–Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Ubrelvy (ubrogepant) — U.S. reported growth YoY (%), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ubrelvy-us-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.